Further exploration into its integration with existing OSAS therapies could redefine the pharmacologic management of obesity-related OSAS
Clinical studies provide direct evidence: GLP-1 analogue therapy significantly reduced sCD163 (a marker of inflammatory macrophage activation), independent of changes in body weight, fructosamine, and HbA1c
At the same time, nearly everyone who comes in for weight loss surgery has already tried a GLP-1
Over time, this whole process helps make skin healthier, leading to a more even skin tone
Others may describe feeling wired but tired, emotionally fragile, or overstimulated in response to normal sensory input
Tsou SH, Luo KS, Huang CN, et al